![Georges Gaudriault](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Georges Gaudriault formerly worked at Obe Therapy Biotechnology SAS, as Scientific Director, Obetherapy, as Scientific Director, Deinove SA, as Vice President, Director-Research & Development, and MedinCell SA, as Chief Scientific Officer.
Dr. Gaudriault received his undergraduate degree, graduate degree, and doctorate degree from the University of Nice Sophia Antipolis.
| Sociétés | Poste | Fin |
|---|---|---|
Obetherapy
 Obetherapy Pharmaceuticals: MajorHealth Technology Operates as biotech company, which develops new drugs for obesity and hypercholesterolemia | Directeur Technique/Scientifique/R&D | - |
| MEDINCELL S.A. | Directeur Technique/Scientifique/R&D | - |
Obe Therapy Biotechnology SAS
 Obe Therapy Biotechnology SAS Medical/Nursing ServicesHealth Services Discovers and develops therapeutics and novel drugs for obesity | Directeur Technique/Scientifique/R&D | - |
| DEINOVE | Directeur Technique/Scientifique/R&D | 01/08/2022 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
University of Nice Sophia Antipolis
 University of Nice Sophia Antipolis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deinove SA
 Deinove SA BiotechnologyHealth Technology Operates as a biotechnology company that develops molecules to the health, nutrition & cosmetic industries | Health Technology |
Obe Therapy Biotechnology SAS
Obe Therapy Biotechnology SAS Medical/Nursing ServicesHealth Services Discovers and develops therapeutics and novel drugs for obesity | Health Services |
MedinCell SA
 MedinCell SA Pharmaceuticals: MajorHealth Technology Provides therapeutic solutions | Health Technology |
Obetherapy
Obetherapy Pharmaceuticals: MajorHealth Technology Operates as biotech company, which develops new drugs for obesity and hypercholesterolemia | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
